Although the clinical development of beloranib was halted due to safety concerns, particularly thromboembolic events, its mechanism, targeting MetAP2 to influence lipid metabolism and energy expenditure, highlights its potential as a therapeutic candidate for obesity and related metabolic disorders. This evidence concerns the gene METAP2 and metabolic disease.